Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-15
    E.g., 2018-10-15

Archive Search

1 results
10:38 PM, May 11, 2017  |  BC Week In Review | Clinical News  |  Clinical Results

Braeburn’s BB0817 risperidone implant meets Phase II/III PK endpoint

data from a Phase II/III trial in more than 50 stabilized schizophrenic patients showing that BB0817
the active metabolite of risperidone -- over 6 months to that of oral risperidone. BB0817
on once-daily 4 mg oral risperidone for ≥8 weeks to receive three 300 mg subcutaneous BB0817